Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ziopharm -- Ignore unavailable to you. Want to Upgrade?

To: PLegee who wrote (7)	2/2/2017 4:49:33 PM
From: The Ox	Read Replies (1) \| Respond to of 14

The run from $2 to $14 was pretty amazing but was way overdone, IMO. Had the stock simply gone up $1 or $1.50 per year since then, I doubt there would be anywhere near that many shorts. $4/2015, $5.50/2016, $7/2017....that would have been understandable. Somewhat understandable that there are massive shorts, with the need to eventually raise more money. Also there are the outstanding warrants .... If they are able to partner soon, at a reasonable price, they could "nuke" the shorts but from what I've read, not sure that's going to happen? As you point out, a solid trial result may be all that's needed at this point in time....